Mapping research trends of transarterial chemoembolization for hepatocellular carcinoma from 2012 to 2021: A bibliometric analysis.
Bibliometrics
CiteSpace
Hepatocellular carcinoma
Transarterial chemoembolization
VOSviewer
Journal
World journal of methodology
ISSN: 2222-0682
Titre abrégé: World J Methodol
Pays: United States
ID NLM: 101628739
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
08
06
2023
revised:
20
07
2023
accepted:
21
08
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second leading cause of cancer-related deaths. Transcatheter arterial chemoembolization (TACE) is a therapy where drugs aimed to slow or halt tumor development are injected into the artery supplying for HCC tissues. A comprehensive analysis of all the articles on TACE for HCC can give us a general understanding of the progress in this field and provide guidance for future research. To analyze and visualize scientific results and research trends in TACE treatment for HCC. The "Web of Science" database was used to identify articles regarding TACE for the treatment of HCC from 2012 to 2021. VOSviewer and CiteSpace were used to analyze the publications trends, collaboration between countries/insti-tutions/authors, and the co-occurrence of keywords, keyword bursts, and references. A total of 5728 original articles on TACE for HCC were retrieved. Regarding the volume of publications, the total number of yearly publications showed a generally increasing trend. China had the highest number of articles, while the United States achieved the highest Hirsch index and highest number of citations. The Sun Yat-sen University in China was most prolific institution. The most active author was Park, J.W from South Korea. The Journal of Vascular and Interventional Radiology (234 articles) was the most productive journal. There is a growing trend toward international collaboration in TACE for HCC. Cluster networks of co-cited references suggested that practice guidelines and targeted therapies are an essential theme in this field. In addition, cluster analysis based on keyword co-occurrence identified the research topic "prediction of TACE treatment" as a hotspot, and propensity score matching can be used to help investigators conduct innovative studies in the future. The results of our bibliometric analysis provide the latest trends and hot topics in TACE therapy for HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second leading cause of cancer-related deaths. Transcatheter arterial chemoembolization (TACE) is a therapy where drugs aimed to slow or halt tumor development are injected into the artery supplying for HCC tissues. A comprehensive analysis of all the articles on TACE for HCC can give us a general understanding of the progress in this field and provide guidance for future research.
AIM
OBJECTIVE
To analyze and visualize scientific results and research trends in TACE treatment for HCC.
METHODS
METHODS
The "Web of Science" database was used to identify articles regarding TACE for the treatment of HCC from 2012 to 2021. VOSviewer and CiteSpace were used to analyze the publications trends, collaboration between countries/insti-tutions/authors, and the co-occurrence of keywords, keyword bursts, and references.
RESULTS
RESULTS
A total of 5728 original articles on TACE for HCC were retrieved. Regarding the volume of publications, the total number of yearly publications showed a generally increasing trend. China had the highest number of articles, while the United States achieved the highest Hirsch index and highest number of citations. The Sun Yat-sen University in China was most prolific institution. The most active author was Park, J.W from South Korea. The Journal of Vascular and Interventional Radiology (234 articles) was the most productive journal. There is a growing trend toward international collaboration in TACE for HCC. Cluster networks of co-cited references suggested that practice guidelines and targeted therapies are an essential theme in this field. In addition, cluster analysis based on keyword co-occurrence identified the research topic "prediction of TACE treatment" as a hotspot, and propensity score matching can be used to help investigators conduct innovative studies in the future.
CONCLUSION
CONCLUSIONS
The results of our bibliometric analysis provide the latest trends and hot topics in TACE therapy for HCC.
Identifiants
pubmed: 37771871
doi: 10.5662/wjm.v13.i4.345
pmc: PMC10523245
doi:
Types de publication
Journal Article
Langues
eng
Pagination
345-358Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Références
Front Oncol. 2022 Jan 21;11:793581
pubmed: 35127501
J Vasc Interv Radiol. 2017 Sep;28(9):1240-1247.e3
pubmed: 28688816
Arch Osteoporos. 2021 Apr 17;16(1):73
pubmed: 33866438
Hepatology. 2020 Jul;72(1):198-212
pubmed: 31698504
Front Pharmacol. 2022 Jan 10;12:809125
pubmed: 35082681
Br J Radiol. 2022 Feb 01;95(1130):20210594
pubmed: 34762499
Cancers (Basel). 2021 Oct 29;13(21):
pubmed: 34771593
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
World J Gastroenterol. 2018 Jan 14;24(2):161-169
pubmed: 29375202
Ir J Med Sci. 2022 Dec;191(6):2493-2499
pubmed: 35064533
Front Pharmacol. 2021 Apr 22;12:646626
pubmed: 33967783
J Hepatol. 2019 Nov;71(5):1051-1052
pubmed: 31515044
J Hepatocell Carcinoma. 2022 Jun 07;9:537-551
pubmed: 35698645
Ann Surg. 2014 Jan;259(1):18-25
pubmed: 24096758
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
J Hepatol. 2019 May;70(5):893-903
pubmed: 30660709
Eur Urol. 2007 Oct;52(4):1238-48
pubmed: 17673361
Hepatol Res. 2022 Sep;52(9):794-803
pubmed: 35698267
Hepatobiliary Surg Nutr. 2020 Aug;9(4):452-463
pubmed: 32832496
BMC Gastroenterol. 2021 Feb 3;21(1):51
pubmed: 33535972
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Cardiovasc Intervent Radiol. 2022 Oct;45(10):1430-1440
pubmed: 35978174
Front Immunol. 2022 Mar 18;13:840956
pubmed: 35371087
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16569-72
pubmed: 16275915
World J Clin Cases. 2021 Jun 26;9(18):4559-4572
pubmed: 34222423
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575
pubmed: 28648803
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Exp Clin Cancer Res. 2021 May 18;40(1):172
pubmed: 34006331
Medicine (Baltimore). 2019 Feb;98(6):e14394
pubmed: 30732183
Tech Vasc Interv Radiol. 2013 Sep;16(3):144-9
pubmed: 23993076
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35710293
J Hepatocell Carcinoma. 2021 May 13;8:403-419
pubmed: 34012930
JAMA Oncol. 2018 May 1;4(5):661-669
pubmed: 29543938
J Cancer Res Clin Oncol. 2023 May;149(5):1873-1882
pubmed: 35788728
Hepatol Res. 2019 Jan;49(1):14-32
pubmed: 30308081
Gastroenterology. 2020 Jul;159(1):335-349.e15
pubmed: 32247694
World J Gastroenterol. 2021 Jan 14;27(2):189-207
pubmed: 33510559
Eur Radiol. 2019 Nov;29(11):5752-5762
pubmed: 30993438
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Bioengineered. 2021 Dec;12(2):11124-11135
pubmed: 34923912
Cancers (Basel). 2022 Jul 08;14(14):
pubmed: 35884392